Know Cancer

forgot password

A Phase 1/2 Trial of BKM120 Combined With Vemurafenib (PLX4032) in BRAFV600E/K Mutant Advanced Melanoma (Novartis Study Number CBKM120ZUS21T)

Phase 1/Phase 2
18 Years
Open (Enrolling)
BRAF Mutant Metastatic Melanoma

Thank you

Trial Information

A Phase 1/2 Trial of BKM120 Combined With Vemurafenib (PLX4032) in BRAFV600E/K Mutant Advanced Melanoma (Novartis Study Number CBKM120ZUS21T)

The phase 1 portion of this trial is a dose escalation study; the phase 2 portion is a
single-stage, single arm prospective clinical trial. All patients will receive continuous
doses of vemurafenib twice a day and BKM120 once a day.

In the phase 1 portion of the study, there will be a 7 day lead-in period to allow for
single dose pharmacokinetic analysis of BKM120 alone. Cycle 1 (28 days) is the dose-limiting
toxicity (DLT) period. During phase 1, vemurafenib and BKM120 doses will be escalated using
a standard 3+3 dose escalation scheme with the goal of identifying the recommended phase 2

In the phase 2 portion of the study, patients will receive continuous doses of vemurafenib
and BKM120 starting on day 1 of the first cycle. In the phase 2 portion of the study,
patients will receive vemurafenib and BKM120 at the recommended phase 2 dose.

Inclusion Criteria

Inclusion Criteria

1. Histologically or cytologically confirmed diagnosis of unresectable stage III and
stage IV melanoma

2. BRAFV600E or BRAFV600K mutation-positive

3. Age ≥ 18 years

4. ECOG performance status ≤ 2

5. Patients must have at least one site of measurable disease (per RECIST for solid

6. Life expectancy of ≥ 12 weeks

7. Adequate bone marrow function as shown by: ANC ≥ 1.5 x 109/L, Platelets ≥ 100 x
109/L, Hb >9 g/dL

8. Total calcium (corrected for serum albumin) within normal limits (biphosphonate use
for malignant hypercalcemia control is not allowed)

9. Magnesium ≥ the lower limit of normal

10. Potassium within normal limits for the institution

11. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) within normal
range (or ≤ 3.0 x upper limit of normal (ULN) if liver metastases are present)

12. Serum bilirubin within normal range (or ≤ 1.5 x ULN if liver metastases are present;
or total bilirubin ≤ 3.0 x ULN with direct bilirubin within normal range in patients
with well documented Gilbert Syndrome)

13. Serum creatinine ≤ 1.5 x ULN or 24-hour clearance ≥ 50 mL/min

14. Serum amylase ≤ ULN

15. Serum lipase ≤ ULN

16. INR ≤ 2

17. Fasting plasma glucose ≤ 120 mg/dL (6.7 mmol/L)

18. Negative serum pregnancy test within 48 hours before starting study treatment

Exclusion Criteria

1. Patients who have received prior treatment with a PI3K inhibitor or a BRAF inhibitor,
prior treatment with sorafenib is permitted.

2. Patients with a known hypersensitivity to BKM120 or to its excipients

3. Patients with untreated brain metastases are excluded; however, patients with
metastatic CNS tumors may participate in this trial, if the patient is > 4 weeks from
therapy completion (incl. radiation and/or surgery) and clinically stable at the time
of study entry

4. Patients with acute or chronic liver, renal disease or pancreatitis

5. Patients with the following mood disorders as judged by the Investigator or a
psychiatrist, or as a result of patient's mood assessment questionnaire:

- Medically documented history of or active major depressive episode, bipolar
disorder (I or II), obsessive-compulsive disorder, schizophrenia, history of
suicidal attempt or ideation, or homicidal ideation

- ≥ CTCAE grade 3 anxiety

- Meets the cut-off score of ≥ 10 in the PHQ-9 or a cut-off of ≥ 15 in the GAD-7
mood scale, respectively, or selects a positive response of "1, 2, or 3" to
question number 9 regarding potential for suicidal thoughts in the PHQ-9
(independent of the total score of the PHQ-9) will be excluded from the study
unless overruled by the psychiatric assessment

6. Patients with diarrhea ≥ CTCAE grade 2

7. Patient has active cardiac disease including any of the following:

- Left ventricular ejection fraction (LVEF) < 50% as determined by MUGA or ECHO

- QTc > 480 msec on screening ECG (using the QTcF formula)

- Personal or family history of prolonged QT syndrome

- Angina pectoris that requires the use of anti-anginal medication

- Ventricular arrhythmias except for benign premature ventricular contractions

- Supraventricular and nodal arrythmias requiring a pacemaker or not controlled
with medication

- Conduction abnormality requiring a pacemaker

- Symptomatic pericarditis

8. Patient has a history of cardiac dysfunction including any of the following:

- Myocardial infarction within the last 6 months, documented by persistent
elevated cardiac enzymes or persistent regional wall abnormalities on assessment
of LVEF function

- History of documented congestive heart failure (New York Heart Association
functional classification III-IV)

- Documented cardiomyopathy

9. Poorly controlled diabetes mellitus (HbA1c > 8 %)

10. Other concurrent severe and/or uncontrolled concomitant medical conditions that could
cause unacceptable safety risks or compromise compliance with the protocol

- Significant symptomatic deterioration of lung function; if clinically indicated,
pulmonary function tests including measures of predicted lung volumes, DLco, O2
saturation at rest on room air should be considered to exclude pneumonitis or
pulmonary infiltrates

11. Impairment of GI function or GI disease that may significantly alter the absorption
of BKM120 (e.g., ulcerative diseases, uncontrolled nausea, vomiting, diarrhea,
malabsorption syndrome, or small bowel resection)

12. Patients who have been treated with any hematopoietic colony-stimulating growth
factors (e.g., G-CSF, GM-CSF) ≤ 2 weeks prior to starting study drug; erythropoietin
or darbepoetin therapy, if initiated at least 2 weeks prior to enrollment, may be

13. Patients who are currently receiving treatment with medication with a known risk to
prolong the QT interval or inducing Torsades de Pointes and the treatment cannot
either be discontinued or switched to a different medication prior to starting study

14. Patients receiving chronic treatment with steroids or another immunosuppressive
agent; topical applications, inhaled sprays, eye drops or local injections are
allowed; patients with previously treated brain metastases, who are on stable low
dose corticosteroids treatment for at least 14 days before start of study treatment
are eligible

15. Patients who have taken herbal medications and certain fruits within 7 days prior to
starting study drug - herbal medications include, but are not limited to St. John's
Wort, Kava, ephedra (ma huang), gingko biloba, DHEA, yohimbe, saw palmetto, and
ginseng; fruits include CYP3A inhibitors: Seville oranges, grapefruit, pomelos, or
exotic citrus fruits

16. Patients who are currently treated with drugs known to be moderate and strong
inhibitors or inducers of isoenzyme CYP3A, and the treatment cannot be discontinued
or switched to a different medication prior to starting study drug; note that
co-treatment with weak inhibitors of CYP3A is allowed).

17. Patients who have received chemotherapy or targeted anticancer therapy ≤ 4 weeks (6
weeks for nitrosourea, antibodies or mitomycin-C) prior to starting study drug must
have resolution of treatment related adverse events to baseline or grade 1 before
starting the trial

18. Patients who have received wide field radiotherapy ≤ 4 weeks or limited field
radiation for palliation ≤ 2 weeks prior to starting study drug or who have not
recovered from side effects of such therapy

19. Patients who have undergone major surgery ≤ 2 weeks prior to starting study drug or
who have not recovered from side effects of such therapy

20. Patients who are currently taking therapeutic doses of warfarin sodium or any other
coumadin-derivative anticoagulant

21. Women who are pregnant or breast feeding or adults of reproductive potential not
employing an effective method of birth control; women of child-bearing potential must
have a negative serum pregnancy test ≤ 72 hours prior to initiating treatment; double
barrier contraceptives must be used through the trial by both sexes; oral,
implantable, or injectable contraceptives are therefore not considered effective for
this study

- Women are considered post-menopausal and not of child bearing potential if they
have had 12 months of natural (spontaneous) amenorrhea with an appropriate
clinical profile (e.g. age appropriate, history of vasomotor symptoms) or six
months of spontaneous amenorrhea with serum FSH levels > 40 mIU/mL [for US only:
and estradiol < 20 pg/mL] or have had surgical bilateral oophorectomy (with or
without hysterectomy) at least six weeks ago. In the case of oophorectomy alone,
only when the reproductive status of the woman has been confirmed by follow up
hormone level assessment is she considered not of child bearing potential.

- Women of child-bearing potential, defined as all women physiologically capable
of becoming pregnant, must use highly effective contraception during treatment
for 3 months in total after study drug discontinuation. Highly effective
contraception is defined as either: True abstinence-when this is in line with
the preferred and usual lifestyle of the subject, periodic abstinence and
withdrawal are not acceptable methods of contraception; Sterilization-have had
surgical bilateral oophorectomy (with or without hysterectomy) or tubal ligation
at least six weeks ago; Male partner sterilization-for female subjects, the
vasectomised male partner should be the sole partner for that patient; Use of a
combination of any two of the following barrier methods of contraception-condom
or Occlusive cap with spermicidal foam/gel/film/cream/vaginal suppository

- Fertile males, defined as all males physiologically capable of conceiving
offspring must use condom during treatment, for 3 months in total after study
drug discontinuation and should not father a child in this period

22. Known diagnosis of human immunodeficiency virus (HIV) infection

23. History of another malignancy within 3 years, except cured or curable basal cell
carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ of
the cervix; patients with lesions curable by excision must have these lesions excised
prior to the initiation of treatment on study

24. Patient is unable or unwilling to abide by the study protocol or cooperate fully with
the investigator

Type of Study:


Study Design:

Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Phase 1 - Safety & Recommended Phase 2 Dose (RP2D)

Outcome Description:

RP2D determined by MTD, post-DLT period toxicity, and pharmacokinetic data

Outcome Time Frame:

28 days

Safety Issue:



United States: Food and Drug Administration

Study ID:

Protocol 11952



Start Date:

June 2012

Completion Date:

July 2015

Related Keywords:

  • BRAF Mutant Metastatic Melanoma
  • BKM120
  • BRAF
  • Melanoma
  • PI3K
  • Melanoma



University of California, San FranciscoSan Francisco, California  94143